Moleculin Biotech, Inc. [MBRX]

Source: 

Company Overview

Moleculin Biotech, Inc is a late-stage pharmaceutical development company currently conducting a pivotal Phase 3 trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML).